Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers worldwide. Majority of patients with HCC are diagnosed in the advanced stages of disease and hence they are only suitable for palliative therapy. TACE (transarterial chemoembolization) is the most commonly used treatment fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Saleem, de Souza, Nurun Nisa, Qiao, Wang, Kasai, Meidai, Keem, Low Jee, Shelat, Vishal G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838811/
https://www.ncbi.nlm.nih.gov/pubmed/27143815
http://dx.doi.org/10.1155/2016/6120143
Descripción
Sumario:Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers worldwide. Majority of patients with HCC are diagnosed in the advanced stages of disease and hence they are only suitable for palliative therapy. TACE (transarterial chemoembolization) is the most commonly used treatment for unresectable HCC. It is however unclear if TACE improves the quality of life (QoL) in patients with HCC. The aim of this review is to evaluate the impact of TACE on QoL of HCC patients.

Ejemplares similares